Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetes

Annales d'Endocrinologie

Volumn 72, Issue 4, 2011, Pages 287-295

  Gautier, J F ^a,b   Sauvanet, J P ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INCRETIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; CELL FUNCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; TREATMENT OUTCOME;

ADAMANTANE; BLOOD GLUCOSE; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FASTING; FOOD; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052351651     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2011.05.005     Document Type: Article

References (40)

1. Bloomgarden Z.T., Dodis R., Viscoli C.M., Holmboe E.S., Inzucchi S.E. Lower baseline glycaemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006, 29:2137-2139.
2. Chapell R., Gould A.L., Alexander C.M. Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes Obes Metab 2009, 11:1009-1016.
3. Cantrell R.A., Alatorre C.I., Davis E.J., Zarotsky V., Le Nestour E., Cuyún Carter G., et al. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diabetes Obes Metab 2010, 12:845-857.
4. Phung O.J., Scholle J.M., Talwar M., Coleman C.I. Effect of non-insulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycaemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
5. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 32:2131-2157.
6. Drucker D.J. The role of gut hormones in glucose homeostasis. J Clin Invest 2007, 117:24-32.
7. Girard J. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab 2008, 34:550-559.
8. Brubaker P.L. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 2010, 151-1984-9.
9. Seino Y., Fukushima M., Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010, 1:8-23.
10. Nauck M., Stöckmann F., Ebert R., Creutzweld W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
11. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008, 4:753-769.
12. Tahrani A.A., Piya M.K., Barnett A.H. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009, 26:249-262. [Erratum in: Adv Ther 2009;26:736].
13. Deacon C.F., Holst J.J. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009, 26:488-499.
14. Sharma M.D. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. Ther Clin Risk Manag 2010, 6:233-237.
15. Evans M. Saxagliptin: a review. Br J Diabetes Vasc Dis 2010, 10:14-20.
16. Onglyza® 5 mg (saxagliptin). Summary of product characteristics. Last updated 1st October 2010. (Accessed November 4, 2010). http://www.ema.europe.eu/.
17. Frederich R., Alexander J.H., Fiedorek F.T., Donovan M., Berglind N., Chen R., et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010, 122:16-27.
18. European Medicines Agency (EMEA): evaluation of medicines for human use. CHMP assessment report for Onglyza (saxagliptine); 2009. Last updated 1st October 2010. EMEA/538345/2009-EMEA/H/C/001039. (Accessed November 4, 2010). http://www.ema.europe.eu/.
19. DeFronzo R.A., Hissa M.N., Garber A.J., Gross J.L., Duan R.Y., Ravichandran S., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009, 32:1649-1655.
20. Chacra A.R., Tan G.H., Apanovitch A., Ravichandran S., List J., Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009, 63:1395-1406.
21. Hollander P., Li J., Allen E., Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009, 94:4810-4819. CV181-013 Investigators.
22. 1c in a pooled analysis of three add-on pivotal randomised phase 3 clinical trials. Diabetologia 2010, 53(Suppl. 1):S327-S328. [Abstract 825-P].
23. American Diabetes Association Clinical Practice Recommendations 2010. Standards of medical care in diabetes - 2010 (Position Statement). Diabetes Care 2010, 33(Suppl.1):S11-S61.
24. Allen E., Donovan M., Berglind N., Maheux P. Efficacy of saxagliptin according to patient baseline characteristics: a pooled analysis of three add-on pivotal randomised phase 3 clinical trials. Diabetologia 2010, 53(Suppl.1):S328. [Abstract 826-P].
25. Levy J.C., Matthews D.R., Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program (Letter). Diabetes Care 1998, 21:2191-2192.
26. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modelling. Diabetes Care 2004, 27:1487-1495.
27. Bosi E., Lucotti P., Setola E., Monti L., Piatti P.M. Incretin-based therapies in type 2 diabetes: a review of clinical results. Diabetes Res Clin Pract 2008, 82(Suppl.2):S102-S107.
28. Monami M., Iacomelli I., Marchionni N., Mannucci E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010, 20:224-235.
29. Chia C.W., Egan J.M. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008, 93:3703-3716.
30. Gilbert M.P., Pratley R.E. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 2009, 122(Suppl.):S11-S24.
31. Cox M.E., Rowell J., Corsino L., Green J.B. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthcare Patient Saf 2010, 2:7-19.
32. Hollander P.A., Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010, 122:71-80.
33. Bloomgarden Z.T., Inzucchi S.E. New treatments for diabetes. N Engl J Med 2007, 356:2222-2223.
34. 1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010, 27:309-317.
35. Sherifali D., Nerenberg K., Pullenayegum E., Cheng J.E., Gerstein H.C. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010, 33:1859-1864.
36. Nauck M.A., Vardarli I. Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. J Diabetes Invest 2010, 1:24-36.
37. Schäfer S.A., Tschritter O., Machicao F., Thamer C., Stefan N., Gallwitz B., et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007, 50:2443-2450. [Erratum in: Diabetologia 2008;51:208; Diabetologia 2009;52:557].
38. Pilgaard K., Jensen C.B., Schou J.H., Lyssenko V., Wegner L., Brøns C., et al. The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 2009, 52:1298-1307.
39. Shu L., Matveyenko A.V., Kerr-Conte J., Cho J.H., McIntosh C.H., Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired β-cell function. Hum Mol Genet 2009, 18:2388-2399.
40. Müssig K., Staiger H., Machicao F., Häring H.-U., Fritsche A. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 2010, 53:2289-2297.